On May 31, 2022 Biond Biologics Ltd., a private, clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, reported that the company will be presenting a joint poster with Sanofi at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2022 Annual Meeting taking place in Chicago, Illinois, June 3-7, 2022 (Press release, Biond Biologics, MAY 31, 2022, View Source [SID1234615301]). The poster presents pre-clinical translational data including potential patient enrichment biomarkers for SAR444881 (BND-22).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster will be presented at:
Developmental Therapeutics—Immunotherapy
Date and Time: 06/05/2022, 8:00 AM – 11:00 AM
Abstract Title: Evaluation of pharmacodynamic and patient enrichment biomarkers for SAR444881, a first-in-class anti-ILT2 monoclonal antibody for cancer immunotherapy.
Abstract ID: 2571
About SAR444881 (BND-22),
Leukocyte Ig-like receptor B1 (LILRB1), also known as immunoglobulin-like transcript 2 (ILT2), is an inhibitory receptor expressed on various immune cells. ILT2 was shown to bind to classical and nonclassical MHC class I molecules and with the highest affinity to HLA-G. Inhibition of ILT2 signaling axis results in impairment of immune cell proliferation, differentiation, phagocytosis, cytotoxicity and cytokine secretion and may therefor serve as a novel target for anti-cancer immunotherapy. SAR444881 (BND-22) is a novel humanized IgG4 monoclonal antagonist antibody that selectively binds to ILT2, blocking its interaction with MHC I molecules, thus preventing the inhibition of ILT2 signaling.
"We previously demonstrated that SAR444881 has robust macrophage and lymphocyte-driven anti-tumor activity in in vitro and in vivo models. The poster presents a joint effort of Biond and Sanofi to explore the pharmacodynamic effect of ILT2 antagonism as well as to inform on combinatorial and patient enrichment strategies for SAR444881 clinical development", said Ilana Mandel, Ph.D., VP R&D at Biond Biologics.